Mepride MF 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg in a sustained-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake, contributing to better glycemic control. The sustained-release formulation ensures a gradual release of the active ingredients, promoting improved patient compliance through reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Mepride MF 2 Tablet SR should be used as part of a comprehensive diabetes management plan, including diet and lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and potential adverse effects is essential during therapy. Consultation with a healthcare professional is recommended before initiating treatment.

Dosage & How to Use